Arvelle Therapeutics Overview
- Founded
- 2019
- Status
- Acquired/Merged
- Employees
- 87
- Latest Deal Type
- M&A
- (Announced)
- Latest Deal Amount
- $960M
- Investors
- 9
Arvelle Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorders. The company's therapies serve patients suffering from central nervous system disorders for debilitating neurological and neuromuscular diseases and are responsible for the development and commercialization of Cenobamate, enabling clinicians to provide proper medical care for focal seizures of patients.
Contact Information
Website
www.arvelletx.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Angelini Pharma
Primary Office
- Zählerweg 6
- 6301 Zug
- Switzerland
+41 044 000 00 00
Arvelle Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 04-Jan-2021 | $960M | 00000 | 00000 | Announced | Generating Revenue |
| 2. Early Stage VC (Series A) | 26-May-2020 | 00000 | 00000 | Completed | Generating Revenue | |
| 1. Corporate | 01-Feb-2019 | Completed | Startup |
Arvelle Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biopharmaceutical company intended to deliver innovative treatments to patients suffering from CNS disorde
Drug Discovery
Zug, Switzerland
87
As of 2021
00000
0000
0000-00-00
000000&0
00000
0000000
lore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
0000 000000000
Emeryville, CA
000
As of 0000
00000
000000 - 000
00000
00000 00
rehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat c
0000 000000000
Bedford, MA
00
As of 0000
00000
0000
0000-00-00
00000000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialArvelle Therapeutics Competitors (32)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zogenix | Formerly VC-backed | Emeryville, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Bedford, MA | 00 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | Burnaby, Canada | 000 | 0000 | 00000000 | 0000 |
| 000000 00000000000 | Formerly VC-backed | Boston, MA | 0000 | 00.000 | 0000 | 00.000 |
| 0000 000000000000 | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
Arvelle Therapeutics Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| llise Lombardo MD | Co-Founder & Chief Medical Officer | ||
| Mark Altmeyer | Co-Founder, President and Chief Executive Officer |
Arvelle Therapeutics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alex Zisson | Self | Board Member | 000 0000 |
| Alexander Pasteur Ph.D | Self | Board Member | 000 0000 |
| Jeong Cho Ph.D | Self | Board Member | 000 0000 |
| Martijn Kleijwegt | Self | Board Member | 000 0000 |
| Michael Bologna | Self | Board Member | 000 0000 |
Arvelle Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialArvelle Therapeutics Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 0000 00 | 20-Feb-2019 | 000000000 00000 00 | 00000 | Buildings and Property |